F10 and peripheral arterial disease: In the clinic, Dual Pathway Inhibition (DPI) with the platelet inhibitor aspirin and low dose Factor Xa (FXa) inhibitor rivaroxaban has been demonstrated to lead to reduced major cardiovascular events in patients with stable CAD or PAD, when compared to monotherapy with aspirin or rivaroxaban6,7.